LEONARD WEINSTOCK: Open Payments
NPI 1467566703 · CREVE COEUR, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$6,055 in 214 payments from 21 companies in 2025. Trend: 2023 $3,749 · 2024 $3,669 · 2025 $6,055
Food & beverage: $4,222Consulting: $1,756Education: $77
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 7 | $1,900 |
| ABBVIE INC. | 62 | $1,258 |
| Janssen Biotech, Inc. | 25 | $672 |
| Takeda Pharmaceuticals U.S.A., Inc. | 23 | $360 |
| Aimmune Therapeutics, Inc. | 13 | $301 |
| Lilly USA, LLC | 14 | $269 |
| PFIZER INC. | 21 | $259 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 12 | $253 |
| Madrigal Pharmaceuticals | 10 | $177 |
| Novo Nordisk Inc | 3 | $154 |
Products named: RINVOQ, TREMFYA, SKYRIZI, OMVOH, XIFAXAN, ENTYVIO, VOWST, DUPIXENT.
Industry payments across MO — which companies pay providers there.
